"comparatorId","comparatorName","targetId","targetName","outcomeIds","outcomeNames","excludedCovariateConceptIds","targetDrug","comparatorDrug","establishedCvd","priorExposure"
5363,"new users of empagliflozin",5357,"new users of canagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","not required","no restrictions"
5364,"new users of empagliflozin with established cardiovascular disease",5361,"new users of canagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","required","no restrictions"
5365,"new users of dapagliflozin",5357,"new users of canagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","not required","no restrictions"
5366,"new users of dapagliflozin with established cardiovascular disease",5361,"new users of canagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","required","no restrictions"
5367,"new users of empagliflozin or dapagliflozin",5357,"new users of canagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","not required","no restrictions"
5368,"new users of empagliflozin or dapagliflozin with established cardiovascular disease",5361,"new users of canagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","required","no restrictions"
5369,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5357,"new users of canagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no restrictions"
5369,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5367,"new users of empagliflozin or dapagliflozin","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no restrictions"
5370,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease ",5368,"new users of empagliflozin or dapagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no restrictions"
5370,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease ",5361,"new users of canagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no restrictions"
5371,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA",5357,"new users of canagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no restrictions"
5371,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA",5367,"new users of empagliflozin or dapagliflozin","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no restrictions"
5372,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease",5361,"new users of canagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no restrictions"
5372,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease",5368,"new users of empagliflozin or dapagliflozin with established cardiovascular disease","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no restrictions"
5387,"new users of empagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure",5373,"new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","not required","at least 1 prior non-metformin AHA exposure"
5388,"new users of empagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure",5374,"new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","not required","no prior non-metformin AHA exposure"
5389,"new users of empagliflozin with no prior exposure to canagliflozin",5375,"new users of canagliflozin with no prior exposure to empagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","not required","no prior exposure to comparator"
5391,"new users of empagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure",5380,"new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","required","at least 1 prior non-metformin AHA exposure"
5392,"new users of empagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure",5381,"new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","required","no prior non-metformin AHA exposure"
5393,"new users of empagliflozin with established cardiovascular disease and no prior exposure to canagliflozin",5382,"new users of canagliflozin with established cardiovascular disease and no prior exposure to empagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;45774751","canagliflozin","empagliflozin","required","no prior exposure to comparator"
5394,"new users of dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure",5373,"new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","not required","at least 1 prior non-metformin AHA exposure"
5395,"new users of dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure",5374,"new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","not required","no prior non-metformin AHA exposure"
5396,"new users of dapagliflozin with no prior exposure to canagliflozin",5376,"new users of canagliflozin with no prior exposure to dapagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","not required","no prior exposure to comparator"
5397,"new users of dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure",5380,"new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","required","at least 1 prior non-metformin AHA exposure"
5398,"new users of dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure",5381,"new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","required","no prior non-metformin AHA exposure"
5399,"new users of dapagliflozin with established cardiovascular disease and no prior exposure to canagliflozin",5383,"new users of canagliflozin with established cardiovascular disease and no prior exposure to dapagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829","canagliflozin","dapagliflozin","required","no prior exposure to comparator"
5400,"new users of empagliflozin or dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure",5373,"new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","not required","at least 1 prior non-metformin AHA exposure"
5401,"new users of empagliflozin or dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure",5374,"new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","not required","no prior non-metformin AHA exposure"
5402,"new users of empagliflozin or dapagliflozin with no prior exposure to canagliflozin",5377,"new users of canagliflozin with no prior exposure to empagliflozin or dapagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","not required","no prior exposure to comparator"
5405,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure",5380,"new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","required","at least 1 prior non-metformin AHA exposure"
5406,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure",5381,"new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","required","no prior non-metformin AHA exposure"
5407,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to canagliflozin",5384,"new users of canagliflozin with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin","5432;5433","Heart failure;BKLE amputation","43526465;44785829;45774751","canagliflozin","empagliflozin or dapagliflozin","required","no prior exposure to comparator"
5410,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5373,"new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","at least 1 prior non-metformin AHA exposure"
5410,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5400,"new users of empagliflozin or dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","at least 1 prior non-metformin AHA exposure"
5411,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5401,"new users of empagliflozin or dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no prior non-metformin AHA exposure"
5411,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5374,"new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no prior non-metformin AHA exposure"
5412,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior exposure to canagliflozin",5378,"new users of canagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no prior exposure to comparator"
5413,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior exposure to empagliflozin or dapagliflozin",5403,"new users of empagliflozin or dapagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","not required","no prior exposure to comparator"
5414,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5405,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","at least 1 prior non-metformin AHA exposure"
5414,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5380,"new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","at least 1 prior non-metformin AHA exposure"
5415,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5406,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no prior non-metformin AHA exposure"
5415,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA",5381,"new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no prior non-metformin AHA exposure"
5417,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin",5408,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no prior exposure to comparator"
5418,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5373,"new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","at least 1 prior non-metformin AHA exposure"
5418,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5400,"new users of empagliflozin or dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","at least 1 prior non-metformin AHA exposure"
5419,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5401,"new users of empagliflozin or dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no prior non-metformin AHA exposure"
5419,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5374,"new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no prior non-metformin AHA exposure"
5420,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior exposure to canagliflozin",5379,"new users of canagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no prior exposure to comparator"
5421,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior exposure to empagliflozin or dapagliflozin",5404,"new users of empagliflozin or dapagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","not required","no prior exposure to comparator"
5422,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5380,"new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","at least 1 prior non-metformin AHA exposure"
5422,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5405,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","at least 1 prior non-metformin AHA exposure"
5426,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5406,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no prior non-metformin AHA exposure"
5426,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA ",5381,"new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no prior non-metformin AHA exposure"
5429,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior exposure to canagliflozin",5386,"new users of canagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no prior exposure to comparator"
5430,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin",5409,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","5432;5433","Heart failure;BKLE amputation","44785829;45774751;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766;1560171;1502905;1559684;1525215;1597756;1550023;1567198;1596977;1547504;1516976;1544838;1594973;1502809;1502855;35602717;19097821;19059796;19033498;19001441;19001409;1530014;1515249","empagliflozin or dapagliflozin","any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA","required","no prior exposure to comparator"
5431,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior exposure to canagliflozin",5385,"new users of canagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","5432;5433","Heart failure;BKLE amputation","43526465;43013884;40239216;40166035;1580747;19122137;44816332;45774435;1583722;40170911;44506754;1529331;40164162;40164161;40164163;1510202;1502826;1516766","canagliflozin","any DPP-4 inhibitor, GLP-1 agonist, or other select AHA","required","no prior exposure to comparator"
